BioSpace News Archive

Findings from SURMOUNT-1, the first investigational phase 3 trial evaluating the safety and efficacy of tirzepatide for the treatment of obesity, were announced, representing a new class of medicines being studied for the treatment of obesity.

Biomea Fusion, Inc. presented new data at the American Diabetes Association Scientific Sessions demonstrating BMF-219’s strong, prolonged glycemic control, insulin sensitization, and HbA1c reduction in two preclinical rat models of diabetes.

vTv Therapeutics Inc. announced that the results from the JDRF-supported mechanistic study assessing effects of TTP399 on ketones during acute insulin withdrawal were published in the Diabetes Obesity and Metabolism journal and presented at The American Diabetes Association’s 82nd Scientific Sessions on June 5th.

Findings from an international study show a once-weekly injection of dulaglutide was superior in improving glycemic control in youth with type 2 diabetes compared to placebo.

Everest Medicines announces that its licensing partner, Gilead Sciences, Inc., reported positive results from the primary analysis of the Phase 3 TROPiCS-02 study of Trodelvy® versus physicians’ choice of chemotherapy in heavily pre-treated HR+/HER2- metastatic breast cancer patients who received prior endocrine therapy, CDK4/6 inhibitors and two to four lines of chemotherapy.

Tumor DNA circulating in the bloodstream can help clinicians decide whether chemotherapy is right for their patients who have undergone surgery for stage II colon cancer, according to a breakthrough study published online in The New England Journal of Medicine and presented at the 2022 American Society of Clinical Oncology Annual Meeting.